BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 33777033)

  • 1. Platelet-Mediated Protection of Cancer Cells From Immune Surveillance - Possible Implications for Cancer Immunotherapy.
    Schmied L; Höglund P; Meinke S
    Front Immunol; 2021; 12():640578. PubMed ID: 33777033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NK Cells in the Tumor Microenvironment.
    Guillerey C
    Adv Exp Med Biol; 2020; 1273():69-90. PubMed ID: 33119876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting natural killer cells in cancer immunotherapy.
    Guillerey C; Huntington ND; Smyth MJ
    Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.
    Barrow AD; Colonna M
    Semin Immunol; 2017 Jun; 31():30-36. PubMed ID: 28935344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between platelets and the cancer immune microenvironment.
    Tuerhong N; Yang Y; Wang C; Huang P; Li Q
    Crit Rev Oncol Hematol; 2024 Jul; 199():104380. PubMed ID: 38718939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and metabolic targeting of natural killer cells to solid tumors.
    Wang J; Matosevic S
    Cell Oncol (Dordr); 2020 Aug; 43(4):577-600. PubMed ID: 32488848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity.
    Kopp HG; Placke T; Salih HR
    Cancer Res; 2009 Oct; 69(19):7775-83. PubMed ID: 19738039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
    Gaggero S; Witt K; Carlsten M; Mitra S
    Front Immunol; 2020; 11():621225. PubMed ID: 33584718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of Natural Killer cell NKG2D and CD226 anti-tumour cascades by platelet cloaked cancer cells: Implications for the metastatic cascade.
    Cluxton CD; Spillane C; O'Toole SA; Sheils O; Gardiner CM; O'Leary JJ
    PLoS One; 2019; 14(3):e0211538. PubMed ID: 30908480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity.
    Placke T; Salih HR; Kopp HG
    J Immunol; 2012 Jul; 189(1):154-60. PubMed ID: 22649191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors.
    Lian G; Mak TS; Yu X; Lan HY
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer cell-mediated immunosurveillance of human cancer.
    Malmberg KJ; Carlsten M; Björklund A; Sohlberg E; Bryceson YT; Ljunggren HG
    Semin Immunol; 2017 Jun; 31():20-29. PubMed ID: 28888619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy.
    Devillier R; Chrétien AS; Pagliardini T; Salem N; Blaise D; Olive D
    J Leukoc Biol; 2021 Jun; 109(6):1071-1088. PubMed ID: 32991746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK cells to cure cancer.
    Di Vito C; Mikulak J; Zaghi E; Pesce S; Marcenaro E; Mavilio D
    Semin Immunol; 2019 Feb; 41():101272. PubMed ID: 31085114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications.
    Farnault L; Sanchez C; Baier C; Le Treut T; Costello RT
    Clin Dev Immunol; 2012; 2012():421702. PubMed ID: 22899948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK Cell Interaction With Platelets and Myeloid Cells in the Tumor Milieu.
    Maurer S; Ferrari de Andrade L
    Front Immunol; 2020; 11():608849. PubMed ID: 33424862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.
    Kaweme NM; Zhou F
    Front Immunol; 2021; 12():683381. PubMed ID: 34220833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive cells in tumor immune escape and metastasis.
    Liu Y; Cao X
    J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
    Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
    JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-derived TGF-β1 mediates the down-modulation of NKG2D expression and may be responsible for impaired natural killer (NK) cytotoxicity in women with endometriosis.
    Guo SW; Du Y; Liu X
    Hum Reprod; 2016 Jul; 31(7):1462-74. PubMed ID: 27130956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.